News
FBIOP
15.76
+1.32%
0.21
Weekly Report: what happened at FBIOP last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at FBIOP last week (0401-0405)?
Weekly Report · 04/08 10:00
Weekly Report: what happened at FBIOP last week (0325-0329)?
Weekly Report · 04/01 09:59
Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary
Fortress Biotech Inc reports results for the quarter ended in December. Revenue rose 21.6% to $19.95 million from a year ago. The company reported a quarterly adjusted loss of 53 cents per share. The mean expectation of five analysts was for a loss of $1.97.
Reuters · 03/28 23:25
Fortress Biotech Inc <FBIO.OQ> expected to post a loss of $1.97 a share - Earnings Preview
Fortress Biotech Inc expected to post a loss of $1.97 a share. The company is expected to report a 9.2% decrease in quarterly revenue to $14.894 million. Wall Street expects the company to report results on March 28.
Reuters · 03/26 11:02
Weekly Report: what happened at FBIOP last week (0318-0322)?
Weekly Report · 03/25 10:01
Weekly Report: what happened at FBIOP last week (0311-0315)?
Weekly Report · 03/18 10:00
Health Rounds: CAR-T therapy shows early promise against brain cancer
Health Rounds: CAR-T therapy shows early promise against brain cancer. A blood test for detecting colorectal cancer that was as accurate as current commercial home tests. Early trials hint at benefit ofCAR-T cells in glioblastoma. The therapy shrank tumors in three separate early-stage trials.
Reuters · 03/14 17:58
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Equitrans Midstream, Crypto-linked stocks
U.S. Stock index futures slip on Monday as investors await key inflation figures this week. Mixed jobs data reinforced expectations that the Fed will begin easing by mid-year. Equitrans Midstream Corp rises after merger with EQT Corp. Crypto-linked stocks jump as bitcoin hits record high.
Reuters · 03/11 11:54
Weekly Report: what happened at FBIOP last week (0304-0308)?
Weekly Report · 03/11 09:58
Weekly Report: what happened at FBIOP last week (0226-0301)?
Weekly Report · 03/04 10:00
Weekly Report: what happened at FBIOP last week (0219-0223)?
Weekly Report · 02/26 10:05
Weekly Report: what happened at FBIOP last week (0212-0216)?
Weekly Report · 02/19 10:06
Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrow
Dividend Stocks News Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrow Feb. 13, 2024 11:01am. The company has declared $0.195/share monthly dividend.
Seeking Alpha · 02/13 16:01
Weekly Report: what happened at FBIOP last week (0205-0209)?
Weekly Report · 02/12 10:01
Weekly Report: what happened at FBIOP last week (0129-0202)?
Weekly Report · 02/05 10:05
Weekly Report: what happened at FBIOP last week (0122-0126)?
Weekly Report · 01/29 10:00
Weekly Report: what happened at FBIOP last week (0115-0119)?
Weekly Report · 01/22 10:02
Weekly Report: what happened at FBIOP last week (0108-0112)?
Weekly Report · 01/15 10:00
Fortress Biotech 9.375% CUM PFD A goes ex-dividend tomorrow
Dividend Stocks News Fortress Biotech 9.375% CUM PFD A goes ex-dividend tomorrow Jan. 10, 2024 1:53 p.m. Fortress biotech, Inc. Declared $0.1953/share monthly dividend.
Seeking Alpha · 01/10 18:53
More
Webull provides a variety of real-time FBIOP stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIOP
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).